For research use only. Not for therapeutic Use.
Fidasimtamab (IBI-315; BH2950) is a recombinant human IgG1 bispecific antibody that targets, binds and inhibits both HER2 and PD-1 and their downstream signalling pathways, and links PD-1 expressing T cells to HER2 expressing tumour cells. Fidasimtamab has potential immunosuppressive and antitumor activity[1].
| Catalog Number | I042103 |
| CAS Number | 2377419-89-9 |
| Purity | ≥95% |
| Reference | [1]. Shijie Jin, et al. Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduct Target Ther. 2022 Feb 7;7(1):39. |
